| DIRECT COMPETITOR COMPARISON | |
| GILD | BMY | GSK | RHHBY.PK | Industry | | Market Cap: | 42.22B | 50.08B | 108.19B | N/A | 97.43M | | Employees: | 3,441 | 35,000 | 99,003 | N/A | 65 | | Qtrly Rev Growth (yoy): | 31.40% | 4.40% | 14.90% | N/A | 19.70% | | Revenue (ttm): | 6.41B | 21.14B | 45.19B | N/A | 14.05M | | Gross Margin (ttm): | 77.47% | 72.39% | 76.27% | N/A | 63.92% | | EBITDA (ttm): | 3.35B | 6.32B | 17.81B | N/A | -12.30M | | Oper Margins (ttm): | 50.19% | 26.65% | 34.30% | N/A | -124.89% | | Net Income (ttm): | 2.43B | 3.79B | 8.12B | N/A | N/A | | EPS (ttm): | 2.586 | 1.933 | 3.18 | N/A | -0.32 | | P/E (ttm): | 18.14 | 13.08 | 13.42 | N/A | 16.41 | | PEG (5 yr expected): | 1.14 | 2.48 | 3.01 | 1.37 | 1.31 | | P/S (ttm): | 6.60 | 2.36 | 2.37 | N/A | 9.54 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.24 | 0.77% | 57.93B | 12.48 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.49 | 0.23% | 13.73B | 15.89 | | Genzyme Corp. | GENZ | 50.87 | 0.97% | 13.50B | 29.00 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.92 | -0.09% | 42.22B | 18.14 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.35 | 0.34% | 8.98B | 1027.55 | | Teva Pharmaceutical Industries Limited | TEVA | 53.38 | 0.21% | 47.03B | 48.84 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.15 | 0.27% | 3.94B | 19.15 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.00 | -0.66% | 2.98B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.20 | -0.55% | 5.56B | 111.66 | | Pfizer Inc. | PFE | 18.28 | -0.16% | 147.51B | 15.18 | | Johnson & Johnson | JNJ | 62.93 | -0.40% | 173.63B | 13.74 | | GlaxoSmithKline plc | GSK | 42.68 | 0.95% | 108.19B | 13.42 | | Sanofi-Aventis | SNY | 39.03 | 1.04% | 101.91B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.74 | 0.80% | 126.60B | 16.69 | | RHHBY.PK | 41.94 | 1.18% | N/A | N/A | | AstraZeneca plc | AZN | 46.03 | 1.72% | 66.74B | 9.24 | | Abbott Laboratories | ABT | 54.206 | -0.06% | 83.84B | 14.69 | | Bristol-Myers Squibb Co. | BMY | 25.28 | 0.48% | 50.08B | 13.08 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | RHHBY.PK | | Inhibition of Cell Migration by Gene Silencing - Measured with the xCELLigence Cell Analysis System from Roche
Wed 8:00am -
Business Wire | | • | GSK | | GlaxoSmithKline Seeks to Commercialize Viread in China for Hepatitis B
Wed 7:11am -
at Seeking Alpha | | • | BMY | | Cramer's Mad Money - Fluor is Flourishing (11/24/09)
Wed 6:22am -
at Seeking Alpha | | • | BMY | | Cramer Cuts Through Bears' Bull to Explain Tuesday's Market
Tue 7:26pm -
at CNBC | | • | GSK | | [video] Topping the Tape
Tue 5:20pm -
at CNBC | | • | GSK | | How Big Pharma Profits from Swine Flu
Tue 3:37pm -
at BusinessWeek | | • | BMY | | 4 Platform Drugmakers to Invest In
Tue 3:20pm -
at Motley Fool | | • | GSK | | Batch of swine flu vaccines studied in Canada
Tue 12:22pm -
AP | | • | GSK | | GlaxoSmithKline pulls swine flu vaccines in Canada
Tue 10:16am -
AP | | • | GSK | | Gilead signs sales deal with Glaxo for Viread
Tue 9:54am -
AP | | • | BMY | | Healthcare Stocks: Safe and Speculative
Tue 8:30am -
TheStreet.com TV | | • | BMY | | Bristol-Myers, Origin Lead High-Flying Stocks
Tue 5:00am -
at TheStreet.com | | • | BMY | | [$$] Remember, Remember the Strength of November
Mon, Nov 23 -
at RealMoney by TheStreet.com | | • | RHHBY.PK | | Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Mon, Nov 23 -
PR Newswire | | • | RHHBY.PK | | Spectrum Pharma: Zevalin Sales Ramp Up
Sun, Nov 22 -
at Seeking Alpha | | • | RHHBY.PK | | Desktop Bug Detector
Fri, Nov 20 -
at Forbes.com | | • | RHHBY.PK | | Biotech Stocks: Senate bill weighs on Allergan, Medicis
Thu, Nov 19 -
at MarketWatch | | • | RHHBY.PK | | 454 Life Sciences Unveils New Bench Top Sequencer, Significant Improvements to the Genome Sequencer FLX System Including 1,000 bp Reads for 2010
Thu, Nov 19 -
Business Wire | | | All Headlines for these symbols... |
|
|
|
0.08% Nasdaq 
0.04 (0.09%) 
Competitors
